VR Logo

Impel NeuroPharma Inc. (IMPL) download report


Healthcare | Biotechnology & Pharma Research

Impel NeuroPharma Inc. (IMPL) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States.

IPO Date: 23-Apr-2021

Chairman, CEO & Pres: Mr. Adrian Adams

Co-Founder and Chief Technology & Devel. Officer: Dr. John D. Hoekman Ph.D.

Listing: NASDAQ: IMPL

Country: United States

Headquarters: Seattle, WA

Website: https://www.Impelnp.com

Key Facts

Market cap: $212.05 Mln

Revenue (TTM): $1.76 Mln

Earnings (TTM): $-92.22 Mln

Cash: $129.84 Mln

Total Debt: $49.70 Mln

Insider's Holding: 1.17%

Liquidity: Low

52 Week range: $5.72 - 34.75

Shares outstanding: 23,175,200

Stock Performance

Time Period Impel NeuroPharma (IMPL) S&P BSE Sensex S&P Small-Cap 600
YTD6.03-9.49-17.79
1 month43.42-2.87-2.72
3 months14.09-8.59-12.17
1 Year24.490.81-15.82
3 Years--10.397.14
5 Years--11.116.20
10 Years--12.0010.33
As on 24-Jun-2022